FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Multiplicom N.V. announces the release of a new gene panel, the CLL MASTR™ Plus kit, to improve the diagnosis of patients with chronic lymphocytic leukemia. This is the most common form of leukemia in adults and has a highly variable outcome. Multiplicom’s test helps to steer the treatment options to stabilize the disease. read more
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into an exclusive license agreement with Taisho Pharmaceutical Co., Ltd. ("Taisho") for the development and commercialisation of Ablynx's anti-TNFa Nanobody, ozoralizumab, in Japan, for the treatment of RA. read more
Spinifex Pharmaceuticals, Inc. (“Spinifex”), a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG (“Novartis”), for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments. read more
FLUIDDA, één van de parels van de Vlaamse medische spitstechnologie, is op 29 juni de gastheer voor de oprichting van MedTech Flanders, de cluster van Vlaamse medtech-organisaties. FLUIDDA’s innovatieve beeldtechnologie en het nieuwe BRONCHOLABTM geven een unieke 3D-inkijk in de longen. De analyses helpen nieuwe geneesmiddelen sneller naar de markt en laten toe betere aerosoltoestellen te ontwikkelen. read more
Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the appointment of Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor. Oncurious is a new oncology company and a joint venture between ThromboGenics NV and VIB, a leading life sciences institute in Flanders (Belgium). read more
Celyad SA (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris: CYAD), announced today the closing of its global offering of 1,460,000 ordinary shares, consisting of an underwritten public offering of 1,168,000 American Depositary Shares (“ADSs”), at a price of $68.56 per ADS, before underwriting discounts, and a concurrent European private placement of 292,000 ordinary shares at a price of €60.25 per share, before underwriting discounts, for gross proceeds of approximately €88.0 million ($100.1 million). All of the ordinary shares and the ADSs were offered by Celyad. read more
The establishment of Confo Therapeutics, a spin-off of VIB and Vrije Universiteit Brussel, was announced today. A consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI contributed € 3 million in the first institutional round of investment. These resources will be used to develop further the innovative CONFO® technology platform and initiate drug discovery programs. read more
Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced the launch of its CE-IVD Idylla™ KRAS Mutation Test, a sample-to-result test for the fast, accurate and reproducible detection of 21 relevant mutations in the KRAS oncogene. read more
reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM). read more
P95, a company dedicated to research in the fields of Pharmacovigilance, Epidemiology and Pharmacoepidemiology announces that the Flemish Government, through the agency for Innovation through Science and Technology (IWT), has awarded a grant of 250,000 EUR to support the development of a Real World Database Analytics Center. read more